



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof

Long-term sequelae of TB and COVID-19 co-infection: prospective cohort evaluation after 1 year.

Denise Rossato Silva , Ana Paula Cere dos Santos ,
Rosella Centis , Lia D'Ambrosio , Giovanni Battista Migliori

PII: S2531-0437(23)00118-6
DOI: <https://doi.org/10.1016/j.pulmoe.2023.05.008>
Reference: PULMOE 1881



To appear in: *Pulmonology*

Received date: 17 March 2023

Accepted date: 24 May 2023

Please cite this article as: Denise Rossato Silva , Ana Paula Cere dos Santos , Rosella Centis , Lia D'Ambrosio , Giovanni Battista Migliori , Long-term sequelae of TB and COVID-19 co-infection: prospective cohort evaluation after 1 year., *Pulmonology* (2023), doi: <https://doi.org/10.1016/j.pulmoe.2023.05.008>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Published by Elsevier Espax00F1;a, S.L.U. on behalf of Sociedade Portuguesa de Pneumologia.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Letter to the Editor

Title: Long-term sequelae of TB and COVID-19 co-infection: prospective cohort evaluation after 1 year.

Authors: Denise Rossato Silva^{1,2,3}, Ana Paula Cere dos Santos^{2,3}, Rosella Centis⁴, Lia D'Ambrosio⁵, Giovanni Battista Migliori⁴.

¹Faculdade de Medicina, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.

²Programa de Pós-Graduação em Ciências Pneumológicas da Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.

³Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil.

⁴Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate Italy.

⁵Public Health Consulting Group, Lugano, Switzerland.

Dear Editor,

The coronavirus disease 2019 (COVID-19) pandemic has shown negative effects on tuberculosis (TB) control. Disruptions to the access to TB services have been reported. In fact, the World Health Organization data show that the pandemic has had a substantial effect on TB trends, with an overall decrease in the number of new TB cases, and an increase in the number of deaths between 2019 and 2020 ¹.

TB and COVID-19 coinfection may be associated with more severe clinical conditions than either disease on its own, leading to greater morbimortality during the acute phase ²⁻⁴. Additionally, post-TB lung disease (PTLD) and post-COVID-19 disorders account for substantial consequences on the health of survivors and often require rehabilitation ^{5,6}. Pulmonary impairment after TB is identified in more than 50% of patients, and post-COVID-19 sequelae may affect up to 80% of COVID-19 survivors ^{5,7}. However, the sequelae of TB and COVID-19 co-infected individuals are largely unknown, and there are no studies so far that have evaluated long-term lung function in these patients.

We conducted a prospective cohort study at Hospital de Clínicas de Porto Alegre, Brazil in collaboration with Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Maugeri, Tradate, Italy. The study was approved by the Ethics Committee of Hospital de Clínicas de Porto Alegre (number 200188). All participants gave their written consent to participation. The study objectives were to assess pulmonary functions tests (PFT, including 6-minute walk test- 6MWT) and quality of life (QoL) in patients with COVID-19 and TB, one year after COVID-19, and to evaluate factors associated with mortality.

Patients ≥ 18 years of age hospitalized with a concomitant diagnosis of COVID-19 and TB (active or sequelae) were evaluated one year after discharge. Patients underwent PFT: spirometry, plethysmography, diffusing capacity of the lung for carbon monoxide (DLCO), and 6MWT. To assess QoL, the EuroQol-5D scale (EQ-5D) was used. In addition, patients were asked about persistent post-COVID-19 symptoms. Categorical comparisons were performed by chi-square test using Yates's correction if indicated, or Fisher's exact test. Continuous variables were compared using the *t*-test or Wilcoxon test. A two-sided *p* value < 0.05 was considered significant.

We included 106 patients with COVID-19 and active TB (n=24) or TB sequelae (n=82), from March 2020 to December 2022. Forty (37.7%) patients died from COVID-19 during the study period. Of the 66 patients who survived COVID-19, 23 underwent PFT (and 6MWT), and were assessed for QoL and persistence of symptoms. Table 1 shows the cohort characteristics. The most common post-COVID-19 ventilatory impairment was restrictive. A large percentage of patients had impaired QoL in the usual activities, anxiety/depression, mobility and pain/discomfort dimensions. All patients reported at least one persistent post-COVID-19 symptom. Active TB patients were younger and had a higher prevalence of current smoking.

Ten patients had PFT pre- and post-COVID-19. There was a reduction in all lung function parameters, but not statistically significant ($p>0.05$ for all comparisons; data not shown). The 6MWT final test was in average 39.4 m lower than the initial test (although not significant, patients lost about 10% of the performance).

Table 2 shows the factors associated with mortality. TB sequelae patients who were older, needed supplemental oxygen and invasive ventilation, and those who had lower total lung capacity (TLC) (%) and DLCO (%) had higher mortality. Active TB patients who needed invasive ventilation had higher mortality.

In this prospective cohort study, we demonstrated that, one year after COVID-19, patients with TB and COVID-19 had abnormal PFT, reduced 6MWT performances, impaired QoL, and persistent symptoms. Furthermore, the mortality of these patients was high (almost 40%).

In the largest cohort of patients with TB and COVID-19 ², mortality was 11%, and the factors associated with death were older age, male gender and invasive ventilation. In a previous study ³, the case fatality rate was 12.3% and deaths were mostly in patients >60 years, with at least one comorbidity. Older age and invasive

ventilation were also risk factors for mortality in the present study. However, we identified a higher mortality, probably because we included only hospitalized patients.

Patients with TB sequelae and COVID-19 who died had lower TLC (%) and DLCO (%) pre-COVID-19, emphasizing the mortality related to PTLT. In fact, PTLT patients have twice the risk of spirometry abnormalities than the general population, and patients surviving COVID-19 may have persistent abnormalities in PFT, such as restrictive ventilatory defects and diffusion impairment⁵. In the present study, a large percentage of patients had restrictive ventilatory pattern, although part of this may be due to sequelae from TB. Although not significant, the loss in 6MWT performances in the final test (about 10%) was relevant.

This study has some limitations. We did not evaluate COVID-19 radiological sequelae, nor pre-COVID-19 QoL. The relatively small sample size of patients with pre- and post-COVID-19 PFT (several patients had severe clinical conditions contraindicating PFT) may have prevented us from finding statistically significant differences.

In conclusion, this study describes the combination of PTLT and post-COVID-19 sequelae, evaluated through PFT (including 6MWT) and QoL. Further studies should evaluate comprehensive strategies to assessment/follow-up and determine the need for pulmonary rehabilitation to improve lung health of patients with these two diseases overlapping.

References

1. World Health Organization. Global Tuberculosis Report 2022.

<https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global->

- tuberculosis-report-2022; 2022 [accessed 01 March 2023].
2. The TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 co-infection: description of the global cohort. *Eur Respir J.* 2022;**59**(3): 2102538. <https://doi.org/10.1183/13993003.02538-2021>.
 3. Tadolini M, Codecasa LR, García-García J-M, Blanc F-X, Borisov S, Alffenaar J-W, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. *Eur Respir J.* 2020;**56**(1):2001398. <https://doi.org/10.1183/13993003.01398-2020>
 4. Visca D, Ong CWM, Tiberi S, Centis R, D'Ambrosio L, Chen B, et al. Tuberculosis and COVID-19 interaction: a review of biological, clinical and public health effects. *Pulmonology.* 2021;**27**(2):151-165. <https://doi.org/10.1016/j.pulmoe.2020.12.012>.
 5. Pontali E, Silva DR, Marx FM, Caminero JA, Centis R, D'Ambrosio L, et al. Breathing Back Better! A State of the Art on the Benefits of Functional Evaluation and Rehabilitation of Post-Tuberculosis and Post-COVID Lungs. *Arch Bronconeumol.* 2022;**58**(11):754–63. <https://doi.org/10.1016/j.arbres.2022.05.010>.
 6. Zampogna E, Migliori GB, Centis R, Cherubino F, Facchetti C, Feci D, et al. Functional impairment during post-acute COVID-19 phase: Preliminary finding in 56 patients. *Pulmonology.* 2021;**27**(5):452-455. <https://doi.org/10.1016/j.pulmoe.2020.12.008>.
 7. Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, van der Zalm MM, et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. *Int J Tuberc Lung Dis.* 2021;**25**(10):797–813. <https://doi.org/10.5588/ijtld.21.0425>.

Table 1. General characteristics of patients.

| Demographic data | Active TB (n=24) | TB Sequelae (n=82) | p value |
|--|---------------------|-----------------------|---------|
| Age, years | 51.3 ± 16.3 | 60.3 ± 14.9 | 0.013 |
| Male sex | 15 (62.5) | 45 (54.9) | 0.668 |
| Smoking status | | | |
| Current smoker | 9 (37.5) | 8 (9.8) | 0.005 |
| Former smoker | 9 (37.5) | 48 (58.5) | |
| Never smoker | 6 (25.0) | 26 (31.7) | |
| Alcohol abuse | 7 (29.2) | 20 (24.4) | 0.837 |
| Intravenous drug user | 5 (20.8) | 7 (8.5) | 0.137 |
| HIV positive | 9 (37.5) | 15 (18.3) | 0.089 |
| TB data | | | |
| CXR at TB diagnosis | | | |
| Unilateral pulmonary cavitory lesions | 1 (4.2) | 3 (3.7) | 0.999 |
| Bilateral pulmonary cavitory lesions | 1 (4.2) | 0 | 0.226 |
| Unilateral pulmonary infiltrates (no cavities) | 4 (16.7) | 38 (46.3) | 0.017 |
| Bilateral pulmonary infiltrates (no cavities) | 14 (58.3) | 32 (39.0) | 0.149 |
| PFT pre-COVID-19 (n=29) | | | |
| Post-BD FEV ₁ (L) | 2.23 ± 0.21 | 2.13 ± 0.98 | 0.892 |
| Post-BD FEV ₁ (%) | 97.0 ± 37.8 | 71.0 ± 29.5 | 0.248 |
| Post-BD FVC (L) | 2.97 ± 0.64 | 2.88 ± 0.95 | 0.902 |
| Post-BD FVC (%) | 92.9 ± 32.0 | 77.1 ± 25.4 | 0.410 |
| Post-BD FEV ₁ /FVC | 83.6 ± 1.13 | 72.6 ± 18.2 | 0.007 |
| TLC (L) | - | 4.93 ± 1.52 | - |
| TLC (%) | - | 82.8 ± 24.8 | - |
| RV (L) | - | 2.17 ± 1.13 | - |
| RV (%) | - | 90.6 ± 33.8 | - |
| DLCO (L) | - | 4.76 ± 2.61 | - |
| DLCO (%) | - | 54.1 ± 25.2 | - |
| 6MWT (m) | - | 385.3 ± 119.7 | - |
| Desaturation in 6MWT | - | 6 (35.3) | - |
| Ventilatory defect pre-COVID-19 | | | |
| Obstructive | 0 | 6 (23.1) | 0.541 |
| Restrictive | 1 (33.3) | 10 (38.5) | |
| Normal | 2 (66.7) | 10 (38.5) | |

| | | | |
|---|--------------|---------------|-------|
| COVID-19 data | | | |
| CXR at COVID-19 diagnosis | | | |
| Unilateral pulmonary cavitary lesions | 1 (4.2) | 1 (1.2) | 0.403 |
| Bilateral pulmonary cavitary lesions | 1 (4.2) | 0 | 0.226 |
| Unilateral pulmonary infiltrates (no cavities) | 0 | 9 (11.0) | 0.204 |
| Bilateral pulmonary infiltrates (no cavities) | 8 (33.3) | 27 (32.9) | 0.999 |
| CT at COVID-19 diagnosis | | | |
| Typical ground glass opacity, unilateral | 4 (16.7) | 7 (8.5) | 0.265 |
| Typical ground glass opacity, bilateral | 7 (29.2) | 20 (24.4) | 0.837 |
| Atypical | 12 (50.0) | 35 (42.7) | 0.688 |
| Supplemental oxygen during COVID-19 | 16 (66.7) | 53 (64.6) | 0.999 |
| Type of ventilation used during COVID-19 | | | |
| Invasive | 9 (37.5) | 28 (34.1) | 0.436 |
| Non-invasive | 2 (8.3) | 16 (19.5) | |
| No ventilation | 13 (54.2) | 38 (46.3) | |
| COVID-19 outcome | | | |
| Discharge | 18 (75.0) | 48 (58.5) | 0.221 |
| Death | 6 (25.0) | 34 (41.5) | |
| PFT post-COVID-19 (n=23)* | | | |
| Post-BD FEV ₁ (L) | 3.10 ± 0.74 | 2.24 ± 1.09 | 0.156 |
| Post-BD FEV ₁ (%) | 83.1 ± 9.1 | 70.6 ± 30.1 | 0.149 |
| Post-BD FVC (L) | 3.61 ± 0.81 | 3.02 ± 1.22 | 0.370 |
| Post-BD FVC (%) | 78.6 ± 8.9 | 76.3 ± 26.8 | 0.767 |
| Post-BD FEV ₁ /CVF | 85.9 ± 2.3 | 73.6 ± 15.7 | 0.004 |
| TLC (L) | 4.88 ± 0.35 | 5.38 ± 1.15 | 0.410 |
| TLC (%) | 77.8 ± 10.7 | 93.5 ± 20.3 | 0.155 |
| RV (L) | 1.54 ± 0.41 | 2.24 ± 0.85 | 0.133 |
| RV (%) | 84.4 ± 30.8 | 113.9 ± 43.9 | 0.222 |
| DLCO (L) | 5.79 ± 0.57 | 4.76 ± 2.41 | 0.175 |
| DLCO (%) | 57.5 ± 7.4 | 54.8 ± 21.4 | 0.709 |
| 6MWT (m) | 416.7 ± 77.1 | 384.2 ± 107.6 | 0.627 |
| Desaturation in 6MWT | 0 | 6 (35.3) | 0.521 |
| Ventilatory defect post-COVID-19 | | | |
| Obstructive | 0 | 3 (15.8) | 0.074 |
| Restrictive | 4 (100) | 9 (47.4) | |
| Normal | 0 | 7 (36.8) | |
| EuroQol-5D Mobility | | | |
| I have no problems walking | 4 (36.4) | 16 (59.3) | |
| I have slight problems walking | 2 (18.2) | 3 (11.1) | |

| | | | |
|--|-------------|-------------|-------|
| I have moderate problems walking | 4 (36.4) | 4 (14.8) | 0.494 |
| I have severe problems walking | 1 (9.1) | 3 (11.1) | |
| I am unable to walk | 0 | 1 (3.7) | |
| EuroQol-5D Self-care | | | |
| I have no problems washing or dressing myself | 9 (81.8) | 19 (70.4) | 0.783 |
| I have slight problems washing or dressing myself | 1 (9.1) | 2 (7.4) | |
| I have moderate problems washing or dressing | 1 (9.1) | 4 (14.8) | |
| I have severe problems washing or dressing | 0 | 1 (3.7) | |
| I am unable to wash or dress myself | 0 | 1 (3.7) | |
| EuroQol-5D Usual activities | | | |
| I have no problems doing my usual activities | 4 (36.4) | 15 (55.6) | 0.507 |
| I have slight problems doing my usual activities | 2 (18.2) | 6 (22.2) | |
| I have moderate problems doing my usual activities | 3 (27.3) | 3 (11.1) | |
| I have severe problems doing my usual activities | 2 (18.2) | 2 (7.4) | |
| I am unable to do my usual activities | 0 | 1 (3.7) | |
| EuroQol-5D Pain and discomfort | | | |
| I have no pain or discomfort | 4 (36.4) | 16 (59.3) | 0.194 |
| I have slight pain or discomfort | 5 (45.5) | 4 (14.8) | |
| I have moderate pain or discomfort | 0 | 3 (11.1) | |
| I have severe pain or discomfort | 1 (9.1) | 1 (3.7) | |
| I have extreme pain or discomfort | 1 (9.1) | 3 (11.1) | |
| EuroQol-5D Anxiety/depression | | | |
| I am not anxious or depressed | 5 (45.5) | 14 (51.9) | 0.687 |
| I am slightly anxious or depressed | 2 (18.2) | 4 (14.8) | |
| I am moderately anxious or depressed | 0 | 2 (7.4) | |
| I am severely anxious or depressed | 2 (18.2) | 2 (7.4) | |
| I am extremely anxious or depressed | 2 (18.2) | 5 (18.5) | |
| EuroQol-5D - Your health today | 68.5 ± 17.7 | 66.7 ± 22.3 | 0.818 |
| Persistent symptoms post-COVID-19 (most common) | | | |
| Olfactory disorders | 2 (40.0) | 11 (52.4) | 0.999 |
| Dyspnea | 1 (20.0) | 10 (47.6) | 0.356 |
| Arthralgia | 2 (40.0) | 7 (33.3) | 0.999 |
| Myalgia | 0 | 7 (33.3) | 0.278 |

| | | | |
|---------|---|----------|-------|
| Fatigue | 0 | 6 (28.6) | 0.298 |
|---------|---|----------|-------|

*Among the 66 survivors, 21 patients could not undergo PFT due to contraindications: 13 due to active respiratory infection; 3 due to tracheostomy; 3 due to recent myocardial infarction; 1 due to aortic aneurysm and 1 due to a recent surgical procedure in the eye region.

Table 2. Factors associated with mortality in TB-COVID-19 patients.

| Demographic data | Active TB | | p Value | TB Sequelae | | p Value |
|-------------------------------|---------------------|-------------------------|---------|---------------------|--------------------------|----------|
| | Survivors (n=18) | Non-survivors* (n=6) | | Survivors (n=48) | Non-survivors* (n=34) | |
| Age, years | 49.6 ± 13.9 | 56.3 ± 22.9 | 0.393 | 55.1 ± 15.4 | 67.5 ± 10.9 | < 0.0001 |
| Male sex | 11 (61.1) | 4 (66.7) | 0.999 | 24 (50.0) | 21 (61.8) | 0.407 |
| Smoking status | | | | | | |
| Current smoker | 8 (44.4) | 1 (16.7) | 0.230 | 4 (8.3) | 4 (11.8) | 0.189 |
| Former smoker | 5 (27.8) | 4 (66.7) | | 25 (52.1) | 23 (67.6) | |
| Never smoker | 5 (27.8) | 1 (16.7) | | 19 (39.6) | 7 (20.6) | |
| Alcohol abuse | 5 (27.8) | 2 (33.3) | 0.999 | 12 (25.0) | 8 (23.5) | 0.999 |
| Intravenous drug user | 3 (16.7) | 2 (33.3) | 0.568 | 4 (8.3) | 3 (8.8) | 0.999 |
| HIV positive | 7 (38.9) | 2 (33.3) | 0.999 | 7 (14.6) | 8 (23.5) | 0.458 |
| TB data | | | | | | |
| PFT pre-COVID-19 | | | | | | |
| Post-BD FEV ₁ (L) | 2.23 ± 0.21 | - | - | 2.29 ± 1.09 | 1.91 ± 0.84 | 0.358 |
| Post-BD FEV ₁ (%) | 97.0 ± 37.8 | - | - | 75.2 ± 30.8 | 65.7 ± 28.4 | 0.436 |
| Post-BD FVC (L) | 2.97 ± 0.64 | - | - | 3.04 ± 0.96 | 2.69 ± 0.94 | 0.373 |
| Post-BD FVC (%) | 92.9 ± 32.0 | - | - | 80.9 ± 26.4 | 72.2 ± 24.4 | 0.398 |
| Post-BD FEV ₁ /FVC | 83.6 ± 1.1 | - | - | 75.3 ± 19.6 | 69.2 ± 16.4 | 0.418 |
| TLC (L) | - | - | - | 5.57 ± 1.49 | 4.39 ± 1.43 | 0.179 |

| | | | | | | |
|---|-----------|----------|-------|---------------|---------------|----------|
| TLC (%) | - | - | - | 99.1 ± 25.1 | 68.9 ± 14.6 | 0.020 |
| RV (L) | - | - | - | 2.55 ± 1.42 | 1.84 ± 0.76 | 0.279 |
| RV (%) | - | - | - | 94.4 ± 35.0 | 86.9 ± 35.5 | 0.721 |
| DLCO (L) | - | - | - | 5.50 ± 3.08 | 4.12 ± 2.12 | 0.325 |
| DLCO (%) | - | - | - | 68.4 ± 21.5 | 41.7 ± 22.2 | 0.035 |
| 6MWT (m) | - | - | - | 394.1 ± 131.4 | 377.4 ± 115.8 | 0.786 |
| Desaturation in 6MWT | - | - | - | | | |
| Ventilatory defect post-TB | | | | | | |
| Obstructive | - | - | - | 4 (28.6) | 2 (16.7) | 0.148 |
| Restrictive | - | - | - | 3 (21.4) | 7 (58.3) | |
| Normal | 2 (66.7) | - | - | 7 (50.0) | 3 (25.0) | |
| COVID-19 data | | | | | | |
| CXR at COVID-19 diagnosis | | | | | | |
| Unilateral pulmonary cavitory lesions | 0 | 1 (16.7) | 0.250 | 1 (2.1) | 0 | 0.999 |
| Bilateral pulmonary cavitory lesions | 0 | 1 (16.7) | 0.250 | - | - | - |
| Unilateral pulmonary infiltrates (no cavities) | - | - | - | 5 (10.4) | 4 (11.8) | 0.999 |
| Bilateral pulmonary infiltrates (no cavities) | 4 (22.2) | 4 (66.7) | 0.129 | 17 (35.4) | 10 (29.4) | 0.740 |
| CT at COVID-19 diagnosis | | | | | | |
| Typical ground glass opacity, unilateral | 4 (22.2) | 0 | 0.539 | 3 (6.3) | 4 (11.8) | 0.441 |
| Typical ground glass opacity, bilateral | 4 (22.2) | 3 (50.0) | 0.307 | 12 (25.0) | 8 (23.5) | 0.999 |
| Atypical | 10 (55.6) | 2 (33.3) | 0.640 | 18 (37.5) | 17 (50.0) | 0.368 |
| Supplemental oxygen during COVID-19 | 10 (55.6) | 6 (100) | 0.066 | 22 (45.8) | 31 (91.2) | < 0.0001 |
| Type of ventilation used during COVID-19 | | | | | | |

| | | | | | | |
|----------------|-----------|----------|-------|-----------|-----------|----------|
| Invasive | 4 (22.2) | 5 (83.3) | 0.003 | 8 (16.7) | 20 (58.8) | < 0.0001 |
| Non-invasive | 1 (5.6) | 1 (16.7) | | 6 (12.5) | 10 (29.4) | |
| No ventilation | 13 (72.2) | 0 | | 34 (70.8) | 4 (11.8) | |

* Causes of death: Active TB group (3 deaths for COVID-19 and 3 deaths for TB + COVID-19); TB sequelae group (all 34 deaths for COVID-19).
Median time do death: Active TB group (13 days [5-27.8 days]) and TB sequelae group (15.5 days [6.8-29.3 days], p=0.691).